Efficient local delivery of FK506 using blocking patches in psoriasis

Zhao, Zihan; Wang, Huaiji; Yao, Lingling; Zhang, Xilin; Yu, Qian; Gu, Jun; Shi, Yu

doi:10.1016/j.jcis.2022.09.146

Cited by 5 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, topical tacrolimus 0.03% and 0.1% ointments reduced the severity of inflammatory changes and positively altered the macroscopic aspect of the scar in the short term (30 days) in a rabbit ear model [182]. Similarly, tacrolimus 0.3% ointment was effective in suppressing TGF-β and SMA, reducing mucin, and improving the quality of collagen fibers and the density of elastic fibers in a rabbit ear HTS model [183]. Tacrolimus is commonly used in the treatment of psoriasis; however, its clinical application is limited by its transdermal drug delivery rate, etc.…”

Section: Tacrolimusmentioning

confidence: 90%

“…The increase in TGF-β receptor I and II expression in TGF-β1-treated KD fibroblasts is suppressed by tacrolimus treatment [179]. It also suppresses smooth muscle actin, reduces mucin, and improves the quality of collagen fibers and the density of elastic fibers [183]. Imiquimod and its metabolite, immune-modulators, induce IFN-α in human blood cells, and IL-1, IL-6, IL-8, and TNF-α in human PBMC cultures in vitro [185,186] Monoclonal antibody Dupilumab Anti-TGF-β1 antibody Anti-VEGF-A antibody Dupilumab, a human monoclonal IgG4 antibody, inhibits IL-4 and IL-13 signaling by binding to the IL-4Rα receptor subunit affecting cellular transcription [195][196][197][198][199].…”

Section: Immunomodulator Tacrolimus Imiquimodmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacotherapy for Keloids and Hypertrophic Scars

Murakami,

Shigeki

2024

IJMS

View full text Add to dashboard Cite

Keloids (KD) and hypertrophic scars (HTS), which are quite raised and pigmented and have increased vascularization and cellularity, are formed due to the impaired healing process of cutaneous injuries in some individuals having family history and genetic factors. These scars decrease the quality of life (QOL) of patients greatly, due to the pain, itching, contracture, cosmetic problems, and so on, depending on the location of the scars. Treatment/prevention that will satisfy patients’ QOL is still under development. In this article, we review pharmacotherapy for treating KD and HTS, including the prevention of postsurgical recurrence (especially KD). Pharmacotherapy involves monotherapy using a single drug and combination pharmacotherapy using multiple drugs, where drugs are administered orally, topically and/or through intralesional injection. In addition, pharmacotherapy for KD/HTS is sometimes combined with surgical excision and/or with physical therapy such as cryotherapy, laser therapy, radiotherapy including brachytherapy, and silicone gel/sheeting. The results regarding the clinical effectiveness of each mono-pharmacotherapy for KD/HTS are not always consistent but rather scattered among researchers. Multimodal combination pharmacotherapy that targets multiple sites simultaneously is more effective than mono-pharmacotherapy. The literature was searched using PubMed, Google Scholar, and Online search engines.

show abstract

Section: Tacrolimusmentioning

confidence: 90%

Section: Immunomodulator Tacrolimus Imiquimodmentioning

confidence: 99%

Pharmacotherapy for Keloids and Hypertrophic Scars

Murakami,

Shigeki

2024

IJMS

View full text Add to dashboard Cite

show abstract

Microneedles as transdermal drug delivery system for enhancing skin disease treatment

Wu,

Yu,

Huang

et al. 2024

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

In Situ Gelling Eye Drops of Tacrolimus with Improved Ocular Delivery and Therapeutic Efficacy

Liu,

Wang

et al. 2024

Biomacromolecules

View full text Add to dashboard Cite

In situ gelling eye drops of tacrolimus (FK506 Gel) were developed to address the formulation challenge of tacrolimus for anterior ocular inflammatory diseases. Both in silico and in vitro investigations were conducted to screen a suitable cyclodextrin species to increase the drug solubility. Guanosine was employed as the gelator and combined with inclusion complexes of tacrolimus in the presence of borate anions to obtain FK506 Gel, which gelated when came into contact with cations in tear fluid and led to the formation of a nanofibrous hydrogel. The versatility of our design to improve the solubility and ocular retention of the hydrophobic drug was demonstrated in vivo with coumarin 6 as a model drug. A mouse dry eye model was used to evaluate the therapeutic effects of FK506 Gel, which, in combination with the biocompatibility study, suggested that FK506 Gel served as a superior treatment for anterior ocular inflammatory diseases.

show abstract

Efficient local delivery of FK506 using blocking patches in psoriasis

Cited by 5 publications

References 50 publications

Pharmacotherapy for Keloids and Hypertrophic Scars

Pharmacotherapy for Keloids and Hypertrophic Scars

Microneedles as transdermal drug delivery system for enhancing skin disease treatment

In Situ Gelling Eye Drops of Tacrolimus with Improved Ocular Delivery and Therapeutic Efficacy

Contact Info

Product

Resources

About